Healthcare entity

Coherus BioSciences

Company CHRS

All 1 tracked stories fall under one category: market-trends. Amgen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Coherus BioSciences appears in 1 tracked Healthcare story from March 8, 2026.

Last mentioned: Mar 8, 2026

RSS updates
Share

Entity pulse

Recent coverage · Coherus BioSciences

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Coherus BioSciences

All 1 tracked stories fall under one category: market-trends. Amgen is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Coherus BioSciences appears in 1 tracked Healthcare story from March 8, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Coherus BioSciences. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q4 2025 Preview

    Analysts set expectations for oncology-driven revenue growth.

  2. Loqtorzi Launch

    Full commercial ramp-up of the first-in-class PD-1 for NPC.

  3. Yusimry Divestiture

    Sale of adalimumab biosimilar to HK King-Friend for $40M.

  4. Cimerli Divestiture

    Coherus sells its ranibizumab biosimilar to Sandoz for $170M.

Stories mentioning Coherus BioSciences 1

Market Trends Neutral

Coherus BioSciences Q4 Preview: Oncology Pivot and Udenyca Growth in Focus

Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures.

2 sources

Coherus BioSciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.